Formulation and Evaluation of Itraconazole Niosomal Gel for Topical Application

  • Manoj Kumar Goyal IPS College of Pharmacy, Shivpuri Link Rd, Gwalior, 474001, (M.P.), India
  • Junaid Qureshi IPS College of Pharmacy, Shivpuri Link Rd, Gwalior, 474001, (M.P.), India


Niosomes have potential applications in topical drug delivery system. Niosomes play an increasingly important role in drug delivery as they can reduce toxicity and modify pharmacokinetic and bio-availability. Topically applied niosomes can increase the residence time of drugs in the stratum corneum and epidermis, while reducing the systemic absorption of the drug. It can act as drug containing reservoirs and the modification of the vesicular compositions or surface properties can adjust the drug release rate and the affinity for the target site. Itraconazole is a triazole derivative useful in the treatment of number of fungal infections. This includes aspergillosis, blastomycosis, coccidioidomycosis, histoplasmosis, and paracoccidioidomycosis. It may be given by mouth or intravenously. Itraconazole niosomes were prepared by thin film hydration method using span 20, 40, 60 (as non-ionic surfactant) and cholesterol (as stable vesicle forming agent). Niosomes were prepared using different ratio of drug: surfactant: cholesterol (1:1:1, 1:2:1, 1:3:1). The niosomal dispersion was evaluated for vesicle size, surface morphology, percent entrapment efficiency, drug content and in vitro drug release. The entrapment efficiency and drug content were calculated at 262 nm using UV spectrophotometer. The entrapment efficiency was found to be 57.2%, 73.2% and 61.2% for the formulations ITZ 20-3, ITZ 40-2 and ITZ 60-1. Itraconazole niosomal gel was prepared using Carbopol 940, glycerol, Triethanolamine and distilled water. Evaluation of niosomal gel was determined by physical appearance, pH, viscosity, drug content, entrapment efficiency and In-vitro permeation studies. The percentage of the drug release from the niosomal gel was found to be 55.67 % for ITZG-2. The present study demonstrates prolongation of drug release, an increase in amount of drug retention into skin and improved permeation across the skin after encapsulation of Itraconazole into niosomal topical gel.

Keywords: Niosomes, Itraconazole, Fungal infection, Thin film hydration method, Carbopol 940


Download data is not yet available.

Author Biographies

Manoj Kumar Goyal, IPS College of Pharmacy, Shivpuri Link Rd, Gwalior, 474001, (M.P.), India

IPS College of Pharmacy, Shivpuri Link Rd, Gwalior, 474001, (M.P.), India

Junaid Qureshi, IPS College of Pharmacy, Shivpuri Link Rd, Gwalior, 474001, (M.P.), India

IPS College of Pharmacy, Shivpuri Link Rd, Gwalior, 474001, (M.P.), India


1. Betageri G, Habib M. Liposomes as drug carriers. Pharm Eng 1994:14:76‐77.
2. Schreier H, Bouwstra JA. Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. J Con Rel 1994:30: 1‐15.
3. Puranajoti P, Patil RT, Sheth PD, Bommareddy G, Dondeti P, Egbaria K. Design and development of topical microemulsion for poorly water-soluble antifungal agents. J Appl Res 2002; 2(1): 27-28.
4. El Laithy HM. El-Shaboury KMF.The development of Cutina lipogels and gel microemulsion for topical administration of fluconazole. AAPS Pharm Sci Tech 2002; 3(4): 35.
5. Mukherjee S, Ray S, Thakur RS. Design and evaluation of Itraconazole loaded solid lipid nanoparticulate system for improving the antifungal therapy. Pakistan J Pharm Sci 2009; 22(2): 131-138.
6. Schreier H. Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. J Con Rel 1994; 30(1): 1-15.
7. Arora R, Jain CP. Advances in niosome as a drug carrier: a review. Asian J Pharm 2007; 1: 29-39.
8. Dan-Bo Y, Jia-Bi Z, Rui-Qin L, Zhi-Qiang H, Jin-Qiu S. Liquid chromatographic method for determination of free and niosome-entrapped nimodipine in mouse plasma and different tissues. Anal Lett 2008; 41(4): 533-542.
9. Naresh RAR, Pillai GK, Udupa N, Chandrashekar G. Anti-inflammatory activity of niosome encapsulated diclofenac sodium in arthritic rats. Indian J Pharmacol 1994; 26(1): 46-48.
10. Jain CP, Vyas SP, Dixit VK. Niosomal system for delivery of rifampicin to lymphatics, Indian J Pharm Sci 2006; 68(5): 575-578.
11. Manosroi A, Jantrawut P, Manosroi J. Anti-inflammatory activity of gel containing novel elastic niosomes entrapped with diclofenac diethyl ammonium. Int J Pharm 2008; 360(1-2): 156-163.
12. Bouwstra JA, Hofland HEH, Spies F, Gorrisand GS, Junginger HE. Liposomes and human stratum corneum in vitro, in Drug Targeting and Delivery Concepts in Dosage form Design, H. E. Junginger, Ed., vol. 1Ellio Horwood, Chichester, UK, 1992 pp.205.
13. Junginger HE, Hofland HEJ, Bouwstra JA. Liposomes and niosomes: interaction with human skin, Cosmet Toiletries.1991; 106: 45-50.
14. Touitou E, Junginger HE, Weiner ND, Nagai T, Mezei M. Liposomes as carriers for topical and transdermal delivery. J Pharm Sci 1994; 83(9): 1189-1203.
15. Saag MS, Dismukes WE. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother 1988; 32(1): 1-8.
16. De Beule K. Itraconazole: pharmacology, clinical experience and future development. Int J Antimicrob Agents 1996; 6(3): 175-181.
17. Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32(suppl 1): 67-87.
18. Jung JY, Yoo SD, Lee SH, Kim KH, Yoon DS, Lee KH. Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique. Int J Pharm 1999; 187(2): 209-218.
19. Brough C, Williams RO. Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery. Int J Pharm 2013; 453(1): 157-66.
20. Shirsand SB, Para MS, Nagendrakumar D, Kanani KM, Keerthy D. Formulation and evaluation of Ketoconazole niosomal gel drug delivery system. Int J Pharm Investig 2012; 2(4): 201-207.
21. Anbarasan B, Rekha S, Elango K, Shriya B, Ramaprabhu S. Optimization of the formulation and in-vitro evaluation of capecitabine niosomes for the treatment of colon cancer. Int J Pharm Sci Res 2013; 4(4): 504-1513.
22. Ruckmani K, Sekar V. Formulation and optimization of Zidovudine niosomes. American Assoc Pharm Sci 2010; 2(3): 1119-1127.
23. Samyuktha RB, Vedha Hari BN. Niosomal formulation of Orlistat: Formulation and in- vitro evaluation. Int J Drug Devel Res 2011; 3(3): 300-311
24. Vyas SP, Khar RK. Targeted and Controlled Drug Delivery Novel Carrier Systems. New Delhi: CBS Publishers and Distributors; 2004 3-13, 40.
25. Sabarikumar K, Varatharajan P, Ilavarasan P, Shaik SM. Bioavailability enhancement of Aceclofenac niosomes containing surfactants and cholesterol. Int J Biol Pharm Res 2012; 3(3): 354-359.
26. Abraham Lingan M, Hasan Sathali AA, Vijayakumar MR, Gokila A. Formulation and evaluation of topcial drug delivery system containing clobetasol propionate niosomes. Sci Revs Chem Commun 2011; 7-17.
27. Jin Y, Wen J, Garg S, Liu D, Zhour Y, Teng L Zhang W. Development of a novel niosomal system for oral delivery of Ginkgo biloba extract. Int J Nanomedicine 2013; 8; 421-430.
28. Rajera R, Nagpal K, Singh SK, Mishra DN. Niosomes: A controlled and novel drug delivery system. Biol Pharm Bull 2011; 34(7): 945- 953.
288 Views | 226 Downloads
How to Cite
Goyal MK, Qureshi J. Formulation and Evaluation of Itraconazole Niosomal Gel for Topical Application. JDDT [Internet]. 25Aug.2019 [cited 18Jun.2021];9(4-s):961-6. Available from: